Clinical trials: Kerato Conjunctivitis Sicca
Keratoconjunctivitis Sicca, Dry Eye
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
- Trial name
- NCT01057147
- Testing
- rebamipide 2% ophthalmic suspension
- Where
- 19 sites in United States
- Volunteers
- 116 people
- Sponsor
- Kubota Vision Inc.
Dry Eye Syndromes
Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
- Trial name
- NCT03821415
- Testing
- RP101
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 104 people
- Sponsor
- Redwood Pharma AB
Keratoconjunctivitis Sicca
Tear Film Break-up Time After Instillation of Artificial Tears
This study is an exploratory trial evaluating the tear film break-up time after a single eye drop instillation of over-the-counter artificial tears.
- Trial name
- NCT00681265
- Testing
- glycerin, polyethylene glycol 400/propylene glycol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Calm Water Therapeutics LLC
Dry Eye Disease
Effect of Cequa™ in Subjects With Dry Eye Disease
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
- Trial name
- NCT04357795
- Testing
- CequaTM (Cyclosporine 0.09%) ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed
The clinical investigation #1122 is a Post Market Clinical Follow Up Study on the EC marked medical device Reinnerva/Lubristil +G, sterile eye drops, compared to Vismed medical device, sterile eye drops, to demonstrate the…
- Trial name
- NCT07422259
- Testing
- Reinnerva/Lubristil +G sterile eye drops (artificial tears), Vismed sterile eye drops (artificial tears)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Medivis SRL
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Dry Eye
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-1 (NCT03334539)
- Testing
- HL036 ophthalmic solution
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Keratoconjunctivitis Sicca
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.
- Trial name
- NCT00037661
- Testing
- INS365 Ophthalmic Solution
- Volunteers
- 222 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface.
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825599
- Testing
- Hydroxypropyl methylcellulose eye drops
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Disease
Safety Study of Tivanisiran to Treat Dry Eye
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
- Trial name
- FYDES (NCT05310422)
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 25 sites in United States
- Volunteers
- 301 people
- Sponsor
- Sylentis, S.A.
Keratoconjunctivitis Sicca
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02139033
- Testing
- Retaine™
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Ocusoft, Inc.
Dry Eye, Keratoconjunctivitis Sicca
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
The purpose of this interventional study is to assess safety, patient tolerability, plug retention rate, and preliminary efficacy in improving the symptoms of Dry Eye Disease (DED) of EXP-TC tacrolimus releasing punctal plug.
- Conditions
- Dry Eye, Keratoconjunctivitis Sicca, Ocular Inflammation
- Trial name
- NCT05618730
- Testing
- punctum plug insertion, Eye Drops, Lubricant
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Eximore Ltd.
Dry Eye Disease
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT06323395
- Testing
- Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops
- Where
- 2 sites in Serbia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease, Dry Eye
PMCF Study to Evaluate Performance and Safety of "CLHA-based Eyedrops" Used to Improve Lacrimal Abnormalities
Tear dysfunction, also known as Dry Eye Disease (DED) is frequently encountered in the clinical practice. It is a multifactorial disease of the ocular surface characterized by insufficient tear production, loss of homeostasis of…
- Conditions
- Dry Eye Disease, Dry Eye, Kerato Conjunctivitis Sicca
- Trial name
- NCT05823961
- Testing
- Cross-linked hyaluronic acid eye drops
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Dry Eye Disease
Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops
The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.
- Trial name
- NCT07540884
- Testing
- Tears Naturale Free lubricating eye drops, Tears Naturale II lubricating eye drops
- Where
- 6 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Alcon Research
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.
- Trial name
- NCT00128245
- Testing
- Pimecrolimus, Vehicle
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Novartis
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
- Trial name
- NCT00987727
- Testing
- carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi)
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Allergan